Generics of Baraclude and Amosartan meet requirements for the Exclusive Sale Rights
As the Patent Linkage System passed the National Assembly, it is expected that some generics will acquire the Prioritized Sale Item Approval (Exclusive Sale Right) this year.
If the system will get enforced on the coming 15th, pharmaceutical companies which succeed a patent challenge and apply f...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
